Please assess the completion status of the following clinical trial:

Trial Title: Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cardiac transplant recipients age 18 years or older receiving cyclosporine or tacrolimus since the time of transplant.~* 12 months after cardiac transplantation but less than 96 months post-transplantation.~Exclusion Criteria:~* Multiple-organ transplant recipients (such as heart-lung, heart-kidney, or heart after kidney transplant recipients).~* Prior or current use of sirolimus or everolimus unless administration was part of a CNI holiday lasting no more than 10 days.~* History of acute rejection within the last 3 months, malignancy within the last 5 years (except for adequately treated basal cell or squamous cell carcinoma of the skin), and human immunodeficiency virus (HIV) patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Group 1: Continuation of CNI regimen
- 2 (Type: EXPERIMENTAL): Group 2: (CNI-Free) Conversion to SRL-based regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).